23/08/2026
New research compares weight loss medications with surgery in people with obesity and Type 2 diabetes.
A large real-world study compared semaglutide, tirzepatide and Sleeve Gastrectomy over 12 months.
Researchers looked at how many people achieved at least 20% weight loss AND an HbA1c below 5.7% at one year:
🔹 Semaglutide: 3.0%
🔹 Tirzepatide: 13.2%
🔹 Sleeve Gastrectomy: 24.0%
Sleeve Gastrectomy was associated with the highest likelihood of achieving both targets, followed by tirzepatide and semaglutide.
However, this was a retrospective observational study, and there were important differences between the groups at the beginning of the study. This means the results don't prove that one treatment is better than another for every person.
The best treatment option depends on your individual health, circumstances and goals.
📖 Leslie DB, Steffen BT, Wise E, et al. 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study. Lancet Diabetes Endocrinol. 2026;14(8):638-648. doi:10.1016/S2213-8587(26)00030-6